Unraveling the mechanism of curcumin in coronary slow flow phenomenon through network pharmacology and molecular docking Authors: Chentian Xue, Jian Kang, Qing Zhu, Xiang Gao, Xize Wu, Yue Yu Published: 2025 ABSTRACT AbstractThe coronary slow flow phenomenon (CSFP) is associated with an increased risk of adverse cardiovascular events, yet standardized treatment is lacking. Curcumin, a natural compound, has shown potential in alleviating angina and improving metabolic risk factors in CSFP, but its underlying molecular mechanisms remain unclear. This study employed an integrated computational strategy. Network pharmacology was used to identify potential targets of curcumin and CSFP from public databases, and common targets were identified. Functional enrichment analysis was performed on the common targets, and a protein-protein interaction network was constructed. Core targets were identified using MCODE and CytoHubba plugins in Cytoscape. Molecular docking evaluated the binding modes and affinities of curcumin with the core targets, while molecular dynamics simulations and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations validated the stability and binding free energies of the complexes. A total of 120 predicted targets of curcumin and 435 CSFP-related targets were identified, yielding 19 common targets. Functional enrichment analysis revealed that curcumin may treat CSFP by modulating inflammatory response, vascular function, cell migration, proliferation, apoptosis, and oxidative stress. These targets were associated with key signaling pathways, including NF-κB, TNF, and HIF-1. Network analysis and topological algorithms identified five core targets: EGFR, ICAM1, NFKB1, PTGS2, and STAT3. Molecular docking results demonstrated that curcumin exhibited excellent binding affinity with all core targets. Molecular dynamics simulations confirmed that the curcumin-core target complexes remained structurally stable during the 100 ns simulation, and MM/GBSA calculations indicated significantly negative binding free energies, suggesting strong binding driving forces. Curcumin may exert therapeutic effects on CSFP through a multi-target mechanism, primarily by interacting with key proteins including EGFR, ICAM1, NFKB1, PTGS2, and STAT3, thereby regulating the NF-κB, TNF, and HIF-1 signaling pathways. This study provides a theoretical foundation for the application of curcumin in CSFP treatment, though further experimental validation is required.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28358-y.Keywords: Coronary slow flow phenomenon, Curcumin, Network pharmacology, Molecular docking, Molecular dynamics simulation, In-silicoSubject terms: Computational biology and bioinformatics, Diseases, Drug discovery Introduction The coronary slow flow phenomenon (CSFP), first described by Tambe et al., is an angiographic characterization defined by delayed opacification of the distal coronary arteries in the absence of significant obstructive stenosis1. With a prevalence of 1% to 7% among patients undergoing coronary angiography for chest pain, CSFP is a clinically relevant condition frequently associated with recurrent angina pectoris, substantially impairing patients’ quality of life2,3. M Moreover, it is linked to an elevated risk of progressive atherosclerosis, obstructive coronary artery disease4, and major adverse cardiovascular events, including acute coronary syndromes and severe arrhythmias5,6. This risk is particularly pronounced in patients over 50 with comorbidities such as hypertension and dyslipidemia6. Currently, no established clinical guidelines exist for CSFP management. Therapeutic strategies are primarily empirical, encompassing lifestyle interventions, pharmacotherapy, and, in some cases, interventional procedures. Common pharmacological agents include statins, beta-blockers, and calcium channel blockers. Statins may improve myocardial perfusion and coronary flow reserve by mitigating inflammation and enhancing endothelial function7–9. Beta-blockers like Nebivolol have been shown to alleviate angina and improve QT dispersion and endothelial function10,11. Similarly, Diltiazem can enhance coronary blood flow12, while the potassium channel opener Nicorandil appears superior to nitroglycerin for symptom relief13. Emerging therapies, such as the selective endothelin-A receptor blocker Zibotentan, have demonstrated efficacy in improving angina symptoms and reducing sublingual nitrate use in CSFP patients14. Additionally, trimetazidine may help normalize arrhythmia predictors and left ventricular diastolic function15, and perindopril has been found to ameliorate QT interval prolongation and impaired diastolic filling16. However, the precise pathogenesis of CSFP remains elusive, rendering most current treatments non-specific. Long-term use of these drugs also raises concerns regarding safety, tolerance, and patient compliance. Crucially, the existing evidence base is largely derived from small-scale studies, resulting in low-grade efficacy evidence and the absence of standardized treatment protocols. Consequently, there is a pressing need for novel, safe, and effective complementary therapies. Curcumin (CAS: 458-37-7), a natural polyphenol derived from turmeric, has garnered significant interest for its potential cardioprotective effects. Its pleiotropic benefits are attributed to a spectrum of biological activities, including lipid-lowering, hypoglycemic, anti-inflammatory, antioxidant, and free radical-scavenging effects17,18. Clinically, curcumin has been reported to alleviate angina in CSFP patients and to ameliorate glycolipid metabolism by reducing fasting and postprandial glucose, glycated hemoglobin, and triglyceride levels, while improving cholesterol ratios19,20. These metabolic benefits underscore its potential to mitigate atherosclerotic cardiovascular risk. A meta-analysis confirmed that curcumin supplementation improves serum levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol in patients with non-communicable diseases21. Another meta-analysis found that nano-curcumin significantly improves waist circumference, fasting blood glucose, HbA1c, and insulin sensitivity in metabolic syndrome patients, alongside beneficial effects on lipid profiles, inflammation, and oxidative stress22. These findings position curcumin as a promising candidate for CSFP treatment, offering benefits that extend beyond angina relief to address underlying metabolic risk factors. Nonetheless, the specific mechanisms by which it exerts its effects in CSFP remain unclear. Furthermore, the clinical evidence remains limited by small sample sizes and methodological constraints, hindering its broad clinical adoption. To bridge this knowledge gap, computational “in-silico” techniques have emerged as powerful tools for the preliminary exploration of complex biological mechanisms. Network pharmacology analyzes drug actions from an integrative, systems-level perspective, making it particularly suitable for deconvoluting the multi-target mechanisms of natural products like curcumin23. Molecular docking provides atomic-level refinement by predicting precise binding modes and affinities between a ligand and its potential targets. Molecular dynamics simulations assess the stability and dynamic behavior of the resulting complexes under near-physiological conditions. The power of such simulations is exemplified by their ability to unravel intricate protein dynamics, such as the clamp opening mechanism in the T4 bacteriophage24, and to decipher the structural consequences of disease-associated mutations25. Furthermore, the integration of docking with free energy calculations has proven instrumental in characterizing specific molecular interactions, as demonstrated in studies of flavonoid-cyclodextrin inclusion complexes26. Building upon this robust methodological foundation, the present study employed a sequential, multi-faceted computational strategy to systematically elucidate the therapeutic mechanism of curcumin in CSFP. This integrated approach first applied network pharmacology to holistically identify potential targets and pathways. The predicted core targets were then validated through molecular docking to simulate their binding modes and affinities with curcumin. The investigation culminated in MD simulations to rigorously evaluate the stability and dynamic behavior of the key complexes. By strategically combining these complementary in-silico techniques, this work aims to provide a robust theoretical foundation and generate testable hypotheses for future experimental research. Materials & methods Acquisition of Curcumin targets The overall research workflow is illustrated in Fig. 1. The canonical SMILES code of curcumin (COC1 = C(C = CC(= C1)/C = C/C(= O)CC(= O)/C = C/C2 = CC(= C(C = C2)O)OC)O) was retrieved from the PubChem database (PubChem CID: 969516) (https://pubchem.ncbi.nlm.nih.gov/, accessed on May 20, 2025)27. Potential protein targets of curcumin were systematically predicted using five complementary databases with the following criteria: SwissTargetPrediction (http://www.swisstargetprediction.ch/, accessed on October 1, 2025)28 and TargetNet (http://targetnet.scbdd.com/, accessed on October 1, 2025)29: Targets with a “probability” ≥ 0.9 were selected; Therapeutic Target Database (TTD) (https://db.idrblab.net/ttd/, accessed on October 1, 2025): Targets labeled as “successful target” and “clinical trial target” were included30; PharmMapper (https://lilab-ecust.cn/pharmmapper/, accessed on October 1, 2025): Targets with a “Z-score” > 0 and “Fit score” > 3.5 were chosen31; Similarity Ensemble Approach (SEA) (https://sea.bkslab.org/, accessed on October 1, 2025): Human targets with a “P-value” < 0.01 and “Max-Tc” > 0.57 were selected32. To ensure high-confidence predictions, stringent, database-specific thresholds were applied. The union of targets from all databases was compiled to establish the final set of predicted curcumin targets. Flow Chart of This Study. Acquisition of CSFP-Related targets Disease-related targets for CSFP were identified by querying the GeneCards (https://www.genecards.org/, accessed on October 1, 2025)33, Online Mendelian Inheritance in Man (OMIM) (https://omim.org/, accessed on October 1, 2025)34, and Ensembl (https://www.ensembl.org/, accessed on October 1, 2025)35 databases using the keywords “coronary slow flow phenomenon” and “coronary slow flow.” All targets from OMIM and Ensembl were included, while targets from GeneCards were filtered by a “relevance score” ≥ 20. Additional targets were supplemented through a manual review of the literature. After merging the results and removing duplicates, a comprehensive CSFP-related target set was established. Identification of common targets and functional enrichment analysis The common targets, defined as the intersection between the predicted curcumin targets and the CSFP-related targets, were considered potential therapeutic targets for curcumin in CSFP. These common targets were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes36 pathway enrichment analyses using the DAVID database (https://davidbioinformatics.nih.gov/, accessed on October 1, 2025)37. Gene Ontology terms encompassing biological processes, cellular components, and molecular functions38, with an false discovery rate (FDR) < 0.05 were considered statistically significant. The results were visualized using the SRplot online platform (http://www.bioinformatics.com.cn/srplot, accessed on October 1, 2025)39. A functional association network was generated using the GeneMANIA database (http://genemania.org/, accessed on October 1, 2025)40. This network illustrates the diverse functional links, including co-expression, shared protein domains, and participation in common pathways, that connect the core targets, providing complementary evidence for their biological relevance in CSFP. Protein-protein interaction (PPI) network and core target screening The common targets were imported into the STRING database (https://cn.string-db.org/, accessed on October 1, 2025)41 to construct a PPI network, with a minimum required interaction confidence score set to 0.7. The resulting network was imported into Cytoscape V3.10.2 software for further analysis42. The “MCODE” plugin was used to identify densely connected network clusters (settings: Degree Cutoff = 2, Node Score Cutoff = 0.2, K-Core = 2, Max Depth = 100)43. Subsequently, the “CytoHubba” plugin was employed to identify hub genes44. Targets with degree, betweenness, and closeness centrality values exceeding the network’s average were defined as core targets. Construction of the “Curcumin-Core Target-Pathway” network A comprehensive “Curcumin-Core Target-Pathway” network was constructed to integrate curcumin, the core targets, and their significantly enriched Kyoto Encyclopedia of Genes and Genomes pathways. This network was visualized using Cytoscape V3.10.2 software42. Construction of the “Transcription Factor-Core Target” network Transcriptional regulators of the core targets were identified using the TRRUST database (https://www.grnpedia.org/trrust/, accessed on October 1, 2025), a curated resource of experimentally validated transcription factor-target interactions45. The search was limited to “Homo sapiens” to construct the “Transcription Factor-Core Target” regulatory network. Construction of the “miRNA-Core Target” network MicroRNAs (miRNAs) targeting the core genes were predicted using four tools: TargetScan (http://www.targetscan.org/vert_72/, accessed on October 1, 2025)46, DIANA-microT (https://dianalab.e-ce.uth.gr/microt_webserver/#/, accessed on October 1, 2025)47, miRmap (https://mirmap.ezlab.org/, accessed on October 1, 2025)48, and TarBase (https://dianalab.e-ce.uth.gr/tarbasev9, accessed on October 1, 2025)49. To ensure high prediction reliability, only miRNAs consistently identified by at least three of the four tools were retained for constructing the “miRNA-Core Target” network. Molecular docking Molecular docking was performed using AutoDock Vina 1.2.7 to investigate the binding modes between curcumin and the core target proteins. The three-dimensional structures of the receptor proteins were obtained from the Protein Data Bank (PDB) database (https://www.rcsb.org/, accessed on October 1, 2025)50. The initial structure of curcumin was retrieved from PubChem and energy-minimized using ChemOffice software. Prior to docking, both the receptor and ligand were preprocessed using AutoDock Tools 1.5.751. The protein receptors were prepared by merging non-polar hydrogen atoms and assigning Gasteiger charges, then exported in PDBQT format. The curcumin ligand was similarly processed by defining rotatable bonds and assigning Gasteiger charges, followed by conversion to PDBQT format. The docking grid was centered on the protein active site region, with a grid box size uniformly set to 26 Å × 26 Å × 26 Å to sufficiently cover the potential binding space of the ligand. For comparative purposes, docking was also performed with known inhibitors of each core target as positive controls. During the analysis of the docking results, the conformation with the lowest binding free energy was selected as the representative binding pose. Visualization was carried out using PyMOL 1.2.652 to enable in-depth analysis of ligand–receptor interactions at the atomic level, including key contacts such as hydrogen bonds and hydrophobic interactions. Molecular dynamics simulation Molecular dynamics simulations were performed using the Groningen Machine for Chemical Simulation (GROMACS) 2022.353. The topology for curcumin was generated with the General Amber Force Field (GAFF) from AmberTools22. The curcumin structure was protonated at pH 7.4, and its electrostatic potential was calculated at the Hartree-Fock (HF)/6-31G* level using Gaussian 16 W to derive restrained electrostatic potential (RESP) charges, which were then incorporated into the topology file. The protein was described using the Amber99sb-ildn force field. The system was solvated in a cubic box of Transferable Intermolecular Potential with 3 Points (TIP3P) water molecules and neutralized by adding an appropriate number of Na⁺ ions. All simulations were conducted under constant temperature (300 K) and pressure (1 bar). The system was first energy-minimized using the steepest descent algorithm. This was followed by equilibration in two phases: 100 ps of canonical ensemble (constant Number of particles, Volume, and Temperature; NVT) and 100 ps of isothermal-isobaric ensemble (constant Number of particles, Pressure, and Temperature; NPT), both with a coupling constant of 0.1 ps. Finally, a production molecular dynamics run was carried out for 100 ns (5,000,000 steps with a 2 fs time step). Trajectory analysis was performed using built-in GROMACS tools to calculate the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), binding free energy by Molecular Mechanics/Generalized Born Surface Area (MM/GBSA), and the free energy landscape. Results Identification of shared targets for Curcumin in CSFP treatment This study systematically identified the potential targets of curcumin and CSFP. Predictions from five databases yielded specific numbers of curcumin targets: SwissTargetPrediction (5), TargetNet (63), TTD (16), PharmMapper (31), and SEA (42). After merging and removing duplicates, a total of 120 unique predicted targets for curcumin were established (Supplementary Table S1). For disease targets, searches using the keyword “CSF” retrieved 185, 75, and 182 targets from the GeneCards, OMIM, and Ensembl databases, respectively. After deduplication, this resulted in 385 unique CSF-related targets (Supplementary Table S2). Searches using the keyword “CSFP” retrieved 227, 76, and 182 targets from the same databases, yielding 426 unique CSFP-related targets after deduplication (Supplementary Table S3). An additional 17 CSFP-related targets were identified through literature mining (Supplementary Table S4). The combination of all CSF and CSFP targets, after removing duplicates, resulted in a final set of 435 disease-related targets (Supplementary Table S5). The intersection between the 120 curcumin targets and the 435 disease targets revealed 19 common targets, suggesting their pivotal role in the therapeutic process (Fig. 2A) (Supplementary Table S6). The PPI network of these common targets comprised 19 nodes and 49 edges, indicating a robust functional interconnectivity (Fig. 2B-C). Identification and Functional Enrichment Analysis of Common Targets for CSFP Treatment with Curcumin. (A) The intersection of 120 curcumin targets and 435 CSFP targets identified 19 common targets. (B) The protein-protein interaction (PPI) network constructed for the 19 common targets consists of 49 edges. In this network, nodes are sorted based on their degree centrality, with darker colors denoting higher degree centrality values. The red circles highlight the targets that possess a high degree centrality. (C) Functional association network of curcumin-CSFP common targets. Nodes represent genes, with the larger labeled nodes indicating the 19 identified common targets. Edges represent functional associations, with colors corresponding to different link types (e.g., co-expression, physical interactions). The highly interconnected nature of the network reveals a tight functional synergy among these targets. (D-F) The (D) biological process, (E) cellular component, molecular function, and (F) pathway analysis of the 19 common targets. Functional enrichment analysis of common targets Functional enrichment analysis of the 19 common targets revealed their significant involvement in diverse biological domains, identified 28 biological processes, 10 cellular components, 5 molecular functions, and 80 signaling pathways (FDR < 0.05) (Supplementary Table S7). Biological processes were predominantly associated with inflammatory regulation (e.g., inflammatory response, regulation of interleukin production, cellular response to lipopolysaccharide), vascular function (e.g., response to angiotensin, angiogenesis), and key cellular events including migration, proliferation, apoptosis, and oxidative stress (Fig. 2D). Cellular components were significantly enriched in membrane microdomains (e.g., membrane raft, caveola), the extracellular matrix, and signaling complexes (e.g., NF-κB p50/p65 complex) (Fig. 2E). Molecular functions primarily involved protein kinase binding, enzyme binding, integrin binding, and protein homodimerization activity (Fig. 2E). Pathways analysis highlighted critical roles in lipid and atherosclerosis, fluid shear stress, cellular senescence, apoptosis, immune signaling (e.g., leukocyte transendothelial migration, RIG-I-like receptor, Toll-like receptor, B cell receptor, and T cell receptor signaling pathway), endocrine regulation (e.g., insulin resistance, endocrine resistance, adipocytokine, relaxin, prolactin, estrogen, apelin, and oxytocin signaling pathway), and various cascades such as Ras, Sphingolipid, Chemokine, HIF-1, TNF, NF-κB, IL-17, MAPK, PI3K-Akt, VEGF, FoxO, and JAK-STAT signaling pathways (Fig. 2F). These results suggest that curcumin may exert its effects on CSFP through multi-target modulation of inflammation, vascular function, cell proliferation, apoptosis, and oxidative stress. Screening and analysis of core therapeutic targets Module and topological analysis of the PPI network identified one high-scoring module (score = 6.667) containing seven genes (EGFR, ICAM1, STAT3, RELA, PTGS2, MMP9, and NFKB1) (Fig. 3A). Subsequent topological filtering defined five core targets: EGFR, ICAM1, NFKB1, PTGS2, and STAT3 (Table 1) (Supplementary Table S8). The PPI network of these core targets demonstrated a highly interconnected structure with 5 nodes and 10 edges (Fig. 3B-C). Functional Enrichment Analysis of Core Targets for CSFP Treatment with Curcumin. (A) Module analysis identified the molecular module with the highest score. (B) Protein-protein interaction networks of the 5 core targets. (C) Functional association network of curcumin-CSFP core targets. (D) The pathway analysis of the 5 core targets. (E) “Curcumin-Core Target- Core Pathway-CSFP” network diagram. Table 1Topological analysis of core targets.Uniprot_CIDCore TargetsDegree CentralityCloseness CentralityBetweenness CentralityP00533EGFR660.4P05362ICAM1660.4P19838NFKB1660.4P35354PTGS2660.4P40763STAT3660.4 Topological analysis of core targets. Functional enrichment analysis of the five core targets pinpointed their involvement in the biological process, “cellular response to mechanical stimulus” and 15 signaling pathways (FDR < 0.05) (Supplementary Table S9). These pathways include the HIF-1, TNF, and NF-κB signaling pathways (Fig. 3D). A “Curcumin-Core Target-Core Pathway” network was constructed to illustrate this central therapeutic axis (Fig. 3E). Construction of the “Transcription Factor-Core Target” network To elucidate upstream transcriptional regulation, the TRRUST database was queried. The analysis identified multiple transcription factors for each core target: EGFR (n = 30), ICAM1 (n = 21), NFKB1 (n = 36), PTGS2 (n = 43), and STAT3 (n = 14) (Fig. 4A) (Supplementary Table S10). Ten key transcription factors (AR, EGR1, HDAC1, NFKB1, PPARG, RELA, SP1, STAT1, STAT3, and TP53) were selected based on regulatory prominence to construct a comprehensive “Transcription Factor-Core Target” network (Fig. 4B). It is noteworthy that NFKB1 and STAT3 themselves act as transcription factors for other core targets. Construction of the “Transcription Factor-Core Target” and “miRNA-Core Target” Networks. (A) (B) Veen diagram identify transcription factors of core targets. (B) “Transcription Factor-Core Target” network diagram. (C) Upset plots identify miRNA of core targets. (D) “miRNA-Core Target” network diagram. The yellow color indicates the miRNAs with the most regulatory functions. Construction of the “miRNA-Core Target” network This study investigated post-transcriptional regulation by predicting upstream miRNAs targeting the core genes. Integrated analysis across multiple prediction tools identified 79, 152, 188, 47, and 289 miRNAs for NFKB1, PTGS2, STAT3, ICAM1, and EGFR, respectively (Fig. 4C) (Supplementary Table S11). Using the criterion of regulating at least three core targets, it was found that hsa-miR-548k and hsa-miR-548n target NFKB1, PTGS2, and STAT3; hsa-miR-664b-3p, hsa-miR-4282, and hsa-miR-3163 target NFKB1, PTGS2, and EGFR; hsa-miR-671-5p, hsa-miR-646, hsa-miR-3680-3p, hsa-miR-129-5p, hsa-miR-545-3p, hsa-miR-320d, hsa-miR-320c, hsa-miR-320b target NFKB1, STAT3, and EGFR; hsa-miR-1277-5p, hsa-miR-5692b, hsa-miR-5692c, hsa-miR-513a-3p, hsa-miR-513c-3p, hsa-miR-7-2-3p, hsa-miR-7-1-3p, hsa-miR-4251, hsa-miR-548c-3p, hsa-miR-495-3p, hsa-miR-5688, hsa-miR-33b-5p target PTGS2, STAT3, and EGFR; hsa-miR-551b-5p target PTGS2, ICAM1, and EGFR; hsa-miR-4755-3p and hsa-miR-221-3p target STAT3, ICAM1, and EGFR. hsa-miR-340-5p target NFKB1, PTGS2, STAT3, and EGFR. A “miRNA-Core Target” interaction network was constructed to visualize these complex regulatory relationships, highlighting both unique and shared miRNA-target interactions (Fig. 4D). Notably, a subsequent literature review revealed a cohesive mechanistic axis centered on hsa-miR-221-3p, which is not only a potential therapeutic target in CSFP but is also regulated by curcumin. This convergence of computational prediction and literature evidence suggests that the “miR-221-3p-STAT3/ICAM1/EGFR” signaling axis may represent a potential mechanism for curcumin intervention in CSFP. Furthermore, the literature review confirmed that several other predicted miRNAs within the network, including miR-671-5p, miR-320d, miR-340-5p, and miR-33b-5p, are also known targets of curcumin. Molecular Docking Molecular docking simulations were performed to investigate curcumin’s interactions with the five core targets. The results demonstrated that curcumin possesses strong binding affinity for all core targets, with predicted binding free energies below − 6.5 kcal/mol. Curcumin exhibited the most stable binding with PTGS2 (−8.2 kcal/mol), followed by EGFR (−7.8 kcal/mol), NFKB1 (−7.2 kcal/mol), STAT3 (−7.2 kcal/mol), and ICAM1 (−6.7 kcal/mol) (Table 2). Table 2Molecular Docking binding energies of Curcumin with the core targets.Uniprot_CIDReceptorPDB_IDLigandBinding Energy (kcal/mol)Center (x, y, z)Docking size (x, y, z)P00533EGFRa, b1M14Curcumin−7.821, −1, 5426, 26, 26P00533EGFRa, b1M14Erlotinib−7.721, −1, 5426, 26, 26P05362ICAM1a, c, d1IC1Curcumin−6.715, 29, 1026, 26, 26P05362ICAM1a, c, d1IC1BIRT-377−6.615, 29, 1026, 26, 26P19838NFKB1a, b, c, dP19838Curcumin−7.2−22, 7, 1726, 26, 26P19838NFKB1a, b, c, dP19838BAY-11–7082−6.4−22, 7, 1726, 26, 26P35354PTGS2a, c, d5f19Curcumin−8.214, 49, 6626, 26, 26P35354PTGS2a, c, d5f19Celecoxib−8.214, 49, 6626, 26, 26P40763STAT3a, b6NJSCurcumin−7.2−15, 25, 1226, 26, 26P40763STAT3a, b6NJSStattic−6.6−15, 25, 1226, 26, 26a Core Targets; b HIF-1 signaling pathway; c TNF signaling pathway; d NF-kappa B signaling pathway. Molecular Docking binding energies of Curcumin with the core targets. a Core Targets; b HIF-1 signaling pathway; c TNF signaling pathway; d NF-kappa B signaling pathway. Detailed structural analysis revealed that curcumin stably occupies the critical functional pockets of these targets through a combination of hydrophobic interactions, hydrogen bonds, and other polar contacts (Fig. 5A-E). The binding poses suggest that curcumin may act as a competitive or allosteric inhibitor for these proteins. Molecular Docking of Curcumin with Core Targets (EGFR, ICAM1, NFKB1, PTGS2, and STAT3). (A-E) The conformational structure of curcumin docking with (A) EGFR, (B) ICAM1, (C) NFKB1, (D) PTGS2, and (E) STAT3. For comparison, this study also performed molecular docking with known inhibitors for each core target. Specifically, the EGFR inhibitor erlotinib (CAS: 183321-69-7)54, PTGS2 inhibitor celecoxib (CAS: 169590-42-5)55, and STAT3 inhibitor Stattic (CAS: 19983-44-9)56 are all well-established specific inhibitors that directly act on their respective targets. Due to the lack of direct and specific small-molecule inhibitors for the NFKB1 subunit and ICAM1, the well-characterized NF-κB pathway inhibitor BAY-11–7082 (CAS: 19542-67-7)57 and the ICAM1/LFA-1 protein-protein interaction inhibitor BIRT-377 (CAS: 213211-10-0)58 were selected as substitutes. The docking results demonstrated strong binding affinities for all these reference inhibitors, with binding energies of −7.8 kcal/mol for erlotinib, −6.6 kcal/mol for celecoxib, −6.4 kcal/mol for Stattic, −8.2 kcal/mol for BAY-11–7082, and − 6.6 kcal/mol for BIRT-377. These results not only validate the reliability of the molecular docking methodology employed in this study but also provide a valuable reference basis for evaluating the binding affinity of curcumin to each target. Binding mode with EGFR Molecular docking analysis positioned curcumin within the kinase domain of EGFR, directly occupying the ATP-binding site (Fig. 5A). The binding mode was stabilized by extensive van der Waals contacts with hydrophobic residues forming the pocket wall, including LEU-694, PHE-699, LEU-768, MET-769, MET-742, and PHE-832. Key hydrogen bonds were formed with the hinge region residues THR-766 and GLN-767, and potential polar interactions were observed with SER-696 and the GLY-697/ALA-698 loop. The binding site is situated adjacent to key regulatory elements, including GLU-738 on the αC-helix, ASP-831 of the DFG motif, and ARG-817, with the overall architecture maintained by the CYS-773/CYS-751 disulfide bridge and GLY-772. This comprehensive binding pose confirms that curcumin functions as an ATP-competitive inhibitor, directly occupying the catalytic cleft and engaging with critical residues for kinase function. Binding mode with ICAM1 Molecular docking predicted that curcumin binds to the LFA-1 interaction domain of ICAM1 with considerable affinity (Fig. 5B). The binding interface was characterized by an extensive network of polar and electrostatic interactions. Curcumin formed contacts with multiple negatively charged residues (GLU-86, ASP-87, GLU-114, GLU-138, GLY-164, and GLU-165) and positively charged residues (ARG-40 and ARG-143), indicating that electrostatic forces are a primary driver of binding. Additional stabilization was provided by polar interactions with GLN-85 and hydrophobic contacts with PRO-142, ALA-141, GLY-139, and VAL-163. As this binding site directly overlaps with the region known for LFA-1 recognition, the results suggest that curcumin may disrupt the ICAM-1/LFA-1 interaction by directly occupying the adhesion interface, thereby potentially inhibiting leukocyte adhesion. Binding mode with NFKB1 Molecular docking revealed that curcumin binds to the DNA-binding region of the NFKB1 p50 subunit (Fig. 5C). The binding interface involved a comprehensive network of interactions. Positively charged residues (ARG-57, ARG-59, LYS-52) and the polar residue TYR-82 likely formed crucial hydrogen bonds or electrostatic attractions with curcumin. This polar network was extended by interactions with HIS-67, SER-66, SER-75, ASN-139, SER-243, and GLU-76. Hydrophobic and structural contributions were provided by PHE-56, GLY-55, GLY-68, and GLY-69. As this binding site directly encompasses key residues critical for DNA recognition, the results indicate that curcumin likely inhibits NF-κB transcriptional activity by sterically hindering the p50-DNA interaction. Binding mode with PTGS2 Molecular docking indicated that curcumin binds with high affinity to PTGS2, embedding deeply within its characteristic hydrophobic substrate channel (Fig. 5D). The complex was stabilized by extensive van der Waals contacts with residues lining the channel wall, including LEU-93, LEU-384, VAL-116, VAL-523, PHE-518, MET-522, TYR-355, PHE-357, ILE-112, TYR-115, ALA-527, PRO-528, and LEU-352. A crucial hydrogen-bond network was formed with polar residues SER-530, GLY-526, and SER-353, and notably with the critical catalytic residue TYR-385. Electrostatic and polar stabilization was further provided by ARG-120 at the channel entrance and ARG-513/GLU-524 pair. This comprehensive binding pose, which shows significant overlap with the arachidonic acid binding site, strongly suggests that curcumin acts as a competitive inhibitor by occupying the substrate channel and directly engaging key catalytic and structural residues. Binding mode with STAT3 Molecular docking demonstrated that curcumin binds to the SH2 domain of STAT3, directly occupying the phosphopeptide-binding pocket (Fig. 5E). The binding mode revealed a multi-faceted interaction network. Critically, curcumin engaged with TRP-474, a central residue for phosphotyrosine recognition. The complex was further stabilized by a potential salt bridge with the ARG-325/GLU-324 pair, and by hydrophobic interactions with ILE-252, ILE-258, ALA-250, CYS-251, PRO-327, CYS-328, and PRO-333. Additional hydrogen bonds were formed with THR-515, SER-514, GLN-247, and ASP-334, while GLY-253 likely provided structural flexibility for the binding site. By comprehensively occupying this functionally essential pocket, the results strongly suggest that curcumin acts as a competitive inhibitor, sterically hindering STAT3’s interaction with phosphopeptides and thereby preventing its dimerization and transcriptional activation. In summary, the molecular docking results strongly suggest that curcumin can function as a multi-target agent against CSFP by directly and stably binding to the core targets, potentially modulating their biological functions through competitive or allosteric inhibition. Molecular dynamics simulation and energetic analysis This study conducted 100 ns MD simulations to evaluate the structural stability and binding affinity of curcumin with the five core targets. The results demonstrated that all five complexes maintained stable conformational dynamics throughout the simulation, with favorable binding free energies. Overall structural stability and dynamics Key structural metrics, including the Rg, RMSD, RMSF, SASA, and intermolecular hydrogen bonds, were analyzed to assess system stability. The low and stable Rg values for all systems indicated the maintenance of compact protein folds. With the exception of the NFKB1 system, which underwent an initial conformational adjustment, the low RMSD values for the complexes, proteins, and ligands confirmed overall structural integrity and equilibrium. Low RMSF values across most residues, particularly in the binding sites, suggested limited flexibility conducive to stable binding. Consistent SASA values implied no major solvation changes, and the presence of sustained hydrogen bonds further corroborated stable ligand-protein interactions (Table 3). Table 3Summary of key stability parameters from molecular dynamics simulations.SystemRg (nm)RMSD_Complex (nm)RMSD_Protein (nm)RMSD_Ligand (nm)RMSF (nm)SASA (nm²)H-BondsEGFR-Curcumin1.98 ± 0.010.29 ± 0.020.23 ± 0.020.09 ± 0.010.13 ± 0.08148.30 ± 3.10~ 4ICAM1-Curcumin2.61 ± 0.020.28 ± 0.030.22 ± 0.030.11 ± 0.020.14 ± 0.06108.56 ± 2.61~ 3NFKB1-Curcumin3.74 ± 0.162.24 ± 0.382.23 ± 0.390.12 ± 0.020.68 ± 0.29547.51 ± 33.47~ 4PTGS2-Curcumin2.42 ± 0.010.25 ± 0.040.20 ± 0.030.10 ± 0.010.12 ± 0.06246.86 ± 3.84~ 1STAT3-Curcumin3.59 ± 0.020.43 ± 0.050.39 ± 0.050.14 ± 0.040.21 ± 0.13286.16 ± 5.52~ 1 Summary of key stability parameters from molecular dynamics simulations. Binding free energy analysis by MM/GBSA The binding affinity of curcumin to each target was quantitatively assessed using the MM/GBSA method. The results revealed strongly favorable (negative) binding free energies (ΔTotal) for all complexes, ranging from − 36.21 to −43.69 kcal/mol (Table 4). In all cases, the highly favorable gas-phase energy (ΔGgas), driven by substantial van der Waals (ΔVDWAALS) and electrostatic (ΔEelec) contributions, was the primary driver of binding. Although the polar solvation energy (ΔGsolvation) was unfavorable (positive), it was outweighed by the dominant gas-phase interactions, resulting in a net negative binding free energy. Table 4MM/GBSA binding free energy components for the core target-curcumin complexes (kcal/mol).Contribution ComponentsEGFR-CurcuminICAM1-CurcuminNFKB1-CurcuminPTGS2-CurcuminSTAT3-CurcuminΔVDWAALS−38.62 ± 1.62−36.00 ± 1.00−38.63 ± 0.47−50.57 ± 0.50−42.68 ± 0.53ΔEelec−47.84 ± 2.00−54.68 ± 2.19−43.65 ± 1.44−14.62 ± 0.60−20.69 ± 2.06ΔEGB49.03 ± 1.0157.05 ± 2.1350.28 ± 1.7133.94 ± 0.2132.14 ± 0.50ΔEsurf−6.26 ± 0.02−4.60 ± 0.05−5.71 ± 0.01−7.43 ± 0.00−4.98 ± 0.02ΔGgas−86.46 ± 2.57−90.68 ± 2.41−82.27 ± 2.47−65.19 ± 0.78−63.37 ± 2.13ΔGsolvation42.77 ± 1.0152.45 ± 2.1344.57 ± 1.7126.51 ± 0.2127.16 ± 0.50ΔTotal−43.69 ± 2.77−38.23 ± 1.22−37.70 ± 1.73−38.68 ± 0.81−36.21 ± 2.18 MM/GBSA binding free energy components for the core target-curcumin complexes (kcal/mol). In summary, the molecular dynamics simulations and energetic analysis consistently demonstrated that curcumin forms stable complexes with all five core targets. The robust structural dynamics and strongly favorable binding affinities provide a solid theoretical foundation for its putative role as a multi-target agent in CSFP treatment, primarily mediated through the suppression of EGFR, ICAM1, NFKB1, PTGS2, and STAT3 (Figs. 6, 7, 8, 9, 10 and 11). Molecular Dynamics Simulation Analysis of the EGFR-Curcumin Complex. (A) Root-mean-square deviation (RMSD) of the complex, protein, and ligand. (B) Radius of gyration (Rg) of the protein. (C) Rg comparison with the Apo-EGFR protein. (D) Root-mean-square fluctuation (RMSF) of residues. (E) Solvent-accessible surface area (SASA). (F) Number of intermolecular hydrogen bonds. (G) Binding free energy contribution of residues. (H) Two-dimensional free energy landscape. (I) Three-dimensional free energy landscape. (J) Secondary structure evolution over time, showing the integrity of key structural elements. Molecular Dynamics Simulation Analysis of the ICAM1-Curcumin Complex. (A) RMSD of the complex, protein, and ligand. (B) Rg of the protein. (C) Rg comparison with the Apo-EGFR protein. (D) RMSF of residues. (E) SASA. (F) Number of intermolecular hydrogen bonds. (G) Binding free energy contribution of residues. (H) Two-dimensional free energy landscape. (I) Three-dimensional free energy landscape. (J) Secondary structure evolution over time, showing the integrity of key structural elements. Molecular Dynamics Simulation Analysis of the NFKB1-Curcumin Complex. (A) RMSD of the complex, protein, and ligand. (B) Rg of the protein. (C) Rg comparison with the Apo-EGFR protein. (D) RMSF of residues. (E) SASA. (F) Number of intermolecular hydrogen bonds. (G) Binding free energy contribution of residues. (H) Two-dimensional free energy landscape. (I) Three-dimensional free energy landscape. (J) Secondary structure evolution over time, showing the integrity of key structural elements. Molecular Dynamics Simulation Analysis of the PTGS2-Curcumin Complex. (A) RMSD of the complex, protein, and ligand. (B) Rg of the protein. (C) Rg comparison with the Apo-EGFR protein. (D) RMSF of residues. (E) SASA. (F) Number of intermolecular hydrogen bonds. (G) Binding free energy contribution of residues. (H) Two-dimensional free energy landscape. (I) Three-dimensional free energy landscape. (J) Secondary structure evolution over time, showing the integrity of key structural elements. Molecular Dynamics Simulation Analysis of the STAT3-Curcumin Complex. (A) RMSD of the complex, protein, and ligand. (B) Rg of the protein. (C) Rg comparison with the Apo-EGFR protein. (D) RMSF of residues. (E) SASA. (F) Number of intermolecular hydrogen bonds. (G) Binding free energy contribution of residues. (H) Two-dimensional free energy landscape. (I) Three-dimensional free energy landscape. (J) Secondary structure evolution over time, showing the integrity of key structural elements. Molecular Dynamics Simulation Analysis of the “Core Target-Curcumin” Complexes. (A-C) RMSD of the (A) complex, (B) protein, and (C) ligand. (D) Rg of the protein. (E) RMSF of residues. (F) SASA. (G) Number of intermolecular hydrogen bonds. Discussion Potential mechanisms of curcumin intervention in CSFP The CSFP is increasingly recognized for its clinical significance, being closely associated with major adverse cardiovascular events and impaired quality of life5,6. As the pathophysiological mechanisms of CSFP are not fully elucidated, current clinical management lacks targeted therapeutics, relying instead on empirical strategies such as nitrates, calcium channel blockers, and statins, which often yield limited and variable efficacy. Current pharmacological interventions for CSFP primarily target specific pathological aspects. For instance, atorvastatin treats CSFP through its pleiotropic effects beyond lipid-lowering, including improving coronary flow reserve, inhibiting inflammation, and enhancing endothelial function8,9; nebivolol ameliorates endothelial function and reduces QT dispersion10,11; while both trimetazidine and perindopril modulate QT interval dispersion15,16. These agents predominantly focus on singular pathological dimensions, such as endothelial correction, electrical stabilization, or isolated anti-inflammatory effects. In contrast, curcumin has demonstrated multi-target potential in cardiovascular diseases through its integrated anti-inflammatory, antioxidant, and vascular protective properties19,20. To elucidate the mechanisms underlying curcumin’s effects on CSFP, this study employed an integrated computational strategy combining network pharmacology, molecular docking, and molecular dynamics simulations. The results suggest that curcumin likely exerts its therapeutic effects primarily by interacting with five core targets, EGFR, ICAM1, NFKB1, PTGS2, and STAT3, and modulating key signaling pathways, including HIF-1, TNF, and NF-κB. Through this network-wide regulation, curcumin may concurrently mitigate endothelial dysfunction, subclinical atherosclerosis, and systemic inflammation, thereby targeting multiple CSFP pathological axes in a coordinated manner. Vascular endothelial dysfunction is widely recognized as a central pathological feature in CSFP2. An intact endothelium maintains vascular homeostasis by balancing vasodilators (e.g., nitric oxide) and vasoconstrictors (e.g., endothelin-1). In CSFP, endothelial injury disrupts this equilibrium, leading to reduced nitric oxide bioavailability and elevated endothelin-1 levels, which contribute to impaired coronary flow. Clinical studies have confirmed that CSFP patients exhibit significantly lower plasma endothelial nitric oxide synthase (eNOS) levels and impaired NO release, alongside elevated endothelin-1 levels59–61. Moreover, CSFP is frequently observed in conditions associated with endothelial dysfunction, such as smoking, obesity, and metabolic syndrome62,63. Curcumin supplementation has been demonstrated to improve flow-mediated dilation, enhance vascular NO bioavailability, and reduce oxidative stress, thereby ameliorating endothelial function64,65. These findings collectively suggest that the improvement of endothelial function represents a key mechanism through which curcumin may treat CSFP. Although patients with CSFP typically show no significant stenosis on coronary angiography, pathological changes related to atherosclerosis remain closely associated with the condition. Pathological studies indicate that CSFP patients exhibit diffuse intimal thickening, extensive coronary wall calcification, and non-obstructive atherosclerotic changes66. Furthermore, CSFP patients demonstrate significantly increased carotid intima-media thickness, which positively correlates with coronary flow velocity, suggesting that CSFP may represent either an early manifestation of atherosclerosis or a localized coronary presentation of systemic disease67. This study identified ICAM1 and PTGS2 as core targets, both of which are key proteins in the formation and progression of atherosclerotic plaques. Curcumin has been demonstrated to delay the progression of atherosclerosis by downregulating adhesion molecule expression and suppressing inflammatory responses, which may represent another crucial mechanism through which curcumin ameliorates CSFP. Accumulating evidence underscores the pivotal role of chronic inflammation in CSFP pathogenesis. Clinical studies consistently report elevated serum levels of pro-inflammatory cytokines (e.g., high-sensitivity C-reactive protein, TNF, IL-6, IL-1β)68–70 and soluble adhesion molecules (e.g., ICAM1, VCAM1, E-selectin) in CSFP patients71,72. The Pan-Immune Inflammation Value has further been identified as an independent predictor for CSFP, reinforcing the link between systemic inflammation and the condition73. The potent anti-inflammatory properties of curcumin form a fundamental basis for its therapeutic potential. The identification of the NF-κB and TNF signaling pathways as central components in curcumin’s network of action aligns well with this clinical evidence. Extensive research confirms that curcumin effectively inhibits the activation of key inflammatory pathways, including NF-κB, and reduces levels of various pro-inflammatory cytokines74,75. Therefore, the multi-targeted suppression of excessive inflammation is considered a core mechanism through which curcumin improves the coronary microcirculatory environment in CSFP. In summary, while current CSFP treatments target individual pathological aspects, curcumin demonstrates a unique multi-target profile, simultaneously addressing endothelial dysfunction, atherosclerotic processes, and systemic inflammation through coordinated regulation of core targets and pathways. This comprehensive mechanism of action positions curcumin as a promising therapeutic candidate for CSFP, potentially offering broader efficacy compared to existing single-mechanism approaches. Core targets of Curcumin intervention in CSFP This study identified five core targets, EGFR, ICAM1, NFKB1, PTGS2, and STAT3, through module and topological analysis of the PPI network. Among these, the upregulation of ICAM1 and NFKB1 in CSFP has been previously established72,76,77, while the regulatory roles of the other targets in CSFP remain unclear. Existing literature indicates that curcumin exerts modulatory effects on these core targets across various disease models. Excessive activation of the epidermal growth factor receptor (EGFR) signaling pathway is implicated in cardiovascular pathologies, including hypertension and atherosclerosis. Inhibiting EGFR has been shown to alleviate macrophage infiltration, inflammatory responses, and oxidative stress in atherosclerotic models78,79, suggesting its relevance to CSFP pathophysiology. The molecular docking results from this study indicate that curcumin binds with high affinity to the kinase domain of EGFR, providing a structural basis for its potential role as a natural EGFR inhibitor. This finding corroborates previous reports of curcumin’s negative regulation of EGFR80–82 and refocuses attention on its relevance to vascular pathology. For instance, curcumin has been confirmed to inhibit EGFR expression, thereby reducing calcification in vascular smooth muscle cells83, a process relevant to the microvascular dysfunction observed in CSFP. Intercellular Adhesion Molecule-1 (ICAM1) is a key mediator of vascular inflammation and endothelial dysfunction, promoting leukocyte adhesion and transmigration into the subendothelial space, a critical step in atherogenesis84. ICAM1 activation also triggers pro-inflammatory signaling and exacerbates endothelial barrier dysfunction85. Elevated ICAM1 expression and soluble levels have been documented in CSFP patients and correlate with the degree of blood flow reduction72,76. Mechanistic studies suggest that NEAT1 upregulates ICAM1 by binding to miR-148b-3p, inhibiting proliferation and promoting apoptosis in endothelial cells under stress72, establishing ICAM1 as a viable therapeutic target. The present finding that curcumin targets ICAM1 is consistent with previous research demonstrating its efficacy in ameliorating atherosclerosis and cardiomyocyte injury via ICAM1 suppression86,87. This suggests that curcumin may alleviate vascular inflammation and improve endothelial function in CSFP by inhibiting ICAM1. Prostaglandin-endoperoxide synthase 2 (PTGS2/COX-2) and its catalytic products (e.g., prostaglandin E2, thromboxane A2) are key mediators of inflammation and vascular tone in cardiovascular diseases such as atherosclerosis and hypertension88,89. PTGS2 expression correlates with lesion severity90, and its inhibition improves endothelial function91. The molecular docking results indicate that curcumin embeds with high affinity into the hydrophobic channel of PTGS2 and interacts with key catalytic residues, providing structural evidence for its potential as a natural PTGS2 inhibitor. This aligns with experimental studies showing that curcumin suppresses PTGS2 expression and reduces prostaglandin production in various cell models92,93. Therefore, direct inhibition of PTGS2 by curcumin, leading to reduced synthesis of pro-inflammatory and vasoconstrictive prostaglandins, may represent an important mechanism for ameliorating vascular dysfunction in CSFP. Nuclear Factor Kappa B (NF-κB) is a central transcription factor in inflammatory responses. Its canonical activation pathway can be triggered by receptors such as Tumor Necrosis Factor Receptor (TNFR) or Toll-Like Receptors (TLRs)94,95. Mutations in the NFKB1 gene (e.g., rs28362491), which encodes the p50 subunit, have been identified as independent predictors of major adverse cardiovascular events96, suggesting a potential association with CSFP prognosis. NF-κB is highly expressed in CSFP patients and contributes to pathogenesis not only by mediating broad inflammatory responses but also by directly impairing vasodilation through suppression of eNOS and NO production77. Consequently, the NF-κB/IL-1β/NO signaling pathway has been proposed as a critical link connecting metabolic syndrome, inflammation, and CSFP, representing a potential therapeutic target77. The identification of NFKB1 as a core target in this study is consistent with confirmed effects of curcumin on improving cardiovascular disease via NF-κB pathway modulation97,98. STAT3, a member of the signal transducer and activator of transcription family, plays crucial roles in cell proliferation, differentiation, survival, inflammation, and angiogenesis. While a direct relationship between STAT3 and CSFP has not been established, its involvement in atherosclerosis, myocardial hypertrophy, and heart failure is well-documented99,100. Curcumin and its derivatives have been shown to inhibit cytokine-induced STAT3 phosphorylation and nuclear translocation101. Therefore, curcumin may delay atherosclerosis and intervene in CSFP by targeting STAT3. Core pathways of Curcumin intervention in CSFP Functional enrichment analysis highlighted the HIF-1, NF-κB, and TNF signaling pathways as significant. The hypoxia-inducible factor-1 (HIF-1) is a transcription factor composed of HIF-1α and HIF-1β subunits. While HIF-1β is constitutively expressed in cells, HIF-1α expression is induced under hypoxic conditions, with significant upregulation when oxygen levels drop below 6%102. Research by Chen et al. using non-targeted metabolomics suggested a pivotal role for the HIF-1 pathway in CSFP development103. Previous studies have also confirmed the close relationship between the HIF-1 signaling pathway and atherosclerosis104,105. In atherosclerotic plaques, HIF-1α is predominantly found in macrophages and smooth muscle cells near the necrotic core, where it promotes disease progression by affecting cell proliferation, migration, angiogenesis, and lipid metabolism106. Inhibition of HIF-1α and HIF-2α has been shown to correct diet-induced metabolic issues, highlighting their potential as therapeutic targets107; for instance, curcumin inhibits lipid metabolism by downregulating the HIF-1α pathway108. However, the HIF-1 pathway plays a dual role: it is protective and adaptive during acute hypoxia by improving tissue perfusion, but this benefit is temporary. Under chronic hypoxia, sustained HIF-1 activation exacerbates oxidative stress and inflammation, thereby promoting pathological vascular remodeling. The reduced blood fluidity in CSFP is likely to cause delayed tissue perfusion and a relative hypoxic state, leading to persistent activation of the HIF-1 pathway109. This sustained activation may therefore represent a critical mechanistic link between CSFP and its downstream pathological consequences. Tumor Necrosis Factor (TNF), a pivotal pro-inflammatory cytokine, exerts multiple pathological effects in vascular dysfunction. It induces the expression of cell adhesion molecules, promoting leukocyte adhesion and infiltration to initiate local inflammation, and stimulates the release of other pro-inflammatory cytokines such as IL-6 and IL-1β, thereby amplifying the inflammatory cascade110. Furthermore, TNF-α impairs nitric oxide bioavailability and promotes the production of vasoconstrictors like endothelin-1, leading to significant vascular endothelial dysfunction. Multiple studies have demonstrated elevated TNF levels in both CSFP animal models and patients68,110,111. A meta-analysis further indicated that curcumin/turmeric supplementation is beneficial in reducing pro-inflammatory cytokines, including IL1 and TNF112. Therefore, targeting the TNF pathway may represent a key mechanism through which curcumin ameliorates CSFP. MiRNA regulatory network MiRNAs are a class of endogenous small non-coding RNA molecules that mediate post-transcriptional gene silencing by binding to their target mRNAs, playing a key regulatory role in the physiological and pathological processes of cardiovascular diseases113. In recent years, research has gradually revealed that specific miRNA expression profiles are closely associated with the occurrence and development of CSFP. In the peripheral blood or vascular tissues of CSFP patients, a series of miRNAs with diagnostic potential show dysregulated expression. For instance, miR-155 and miR-22 are both highly expressed in the plasma of CSFP patients and are considered potential circulating biomarkers111,114,115. Functionally, these dysregulated miRNAs collectively promote the CSFP phenotype by modulating endothelial function, inflammation, and cell apoptosis. miR-126, a core molecule in maintaining vascular endothelial homeostasis, shows expression levels significantly correlated with CSFP116. Meanwhile, miR-342-3p has been found to promote the proliferation of human umbilical vein endothelial cells under hypoxia/reoxygenation conditions by targeting FPR1, thereby exerting a protective effect117. miR-155 has been demonstrated to exacerbate pro-atherosclerotic inflammation by suppressing the expression of SOCS1 protein118. Additionally, miR-181b-5p and miR-128-3p have been identified as potential targets for intervening in CSFP by influencing inflammation and endothelial function69,119. At the microvascular level, miR-30e-5p can alleviate hypoxia-induced cardiomyocyte apoptosis by inhibiting the pro-apoptotic protein BIM, suggesting its potential in treating coronary microembolization-related injury120. These findings not only construct an miRNA regulatory network for CSFP but also provide new ideas for its treatment. For example, atorvastatin has been confirmed to improve the function of endothelial progenitor cells by regulating the miR-221/VEGFA axis, offering a partial mechanistic explanation for its efficacy in treating CSFP121. Building upon this established miRNA regulatory landscape in CSFP, the integrated analysis further reveals that curcumin likely plays a critical role by targeting multiple core proteins, including EGFR, ICAM1, NFKB1, PTGS2, and STAT3. Furthermore, database predictions identified 29 potential miRNAs associated with these targets, suggesting their possible involvement in the CSFP-related signaling network regulated by curcumin. Among these, miR-221-3p emerges as a particularly significant candidate. In addition to its documented protective role in CSFP through the promotion of endothelial progenitor cell function121, miR-221-3p is widely recognized as a master regulator of cardiovascular pathophysiology, critically involved in modulating endothelial cell development, differentiation, and the activation of angiogenesis122–124. The convergence of its broad regulatory functions, specific involvement in CSFP, and evidence of its modulation by curcumin125,126 supports its role as a pivotal downstream mediator118,119. These findings not only identify miR-221-3p as a target but also position the “miR-221-3p-STAT3/ICAM1/EGFR” pathway as a potential central signaling axis through which curcumin may coordinate its therapeutic effects on endothelial function and vascular repair in CSFP. Furthermore, a literature review of other predicted miRNAs revealed that curcumin has been experimentally validated to regulate several of them in diverse disease models. These include miR-671-5p127, miR-320d127, miR-340-5p128–130, and miR-33b-5p131,132, all of which are encompassed within the current prediction. The fact that a biologically active subset of the algorithm-predicted miRNAs are known pharmacological targets of curcumin significantly strengthens the credibility of the overall regulatory network. Summary, limitations, and future perspectives Summary and innovative insights This study integrated network pharmacology, molecular docking, and molecular dynamics simulations to systematically elucidate the multi-target and multi-pathway synergistic mechanism of CSFP. The results demonstrate that curcumin has inhibitory effects on core targets such as EGFR, ICAM1, NFKB1, PTGS2, and STAT3, thereby regulating key signaling pathways including HIF-1, TNF, and NF-κB. This multi-faceted intervention contributes to the therapeutic effects of curcumin in anti-inflammatory response, improving vascular endothelial function, and alleviating oxidative stress. Methodologically, the systematic computational strategy not only constructed a “target-pathway” network but also revealed upstream regulatory roles of transcription factors and miRNAs (e.g., miR-221-3p), offering novel insights into the molecular mechanisms of CSFP. These findings provide a theoretical basis for the clinical translation of curcumin and suggest new candidate targets for multi-target drug development. Compared to single-target agents, the multi-target characteristic of curcumin enables simultaneous intervention in the complex pathological network of CSFP, demonstrating a potential for synergistic therapeutic effects. This mode of action may not only enhance efficacy but also help reduce the risk of drug resistance caused by compensatory pathway activation or target mutations, thereby offering a more sustained therapeutic response. However, multi-target intervention may also pose potential off-target risks and safety concerns. It is worth emphasizing that curcumin, as a naturally derived compound with a history of long-term dietary use, has a clinically recognized safety profile to some extent, which provides a favorable foundation for its further development. Nonetheless, this also highlights the necessity for future systematic safety evaluations. Limitations and future directions Notwithstanding these insights, several limitations must be acknowledged. Firstly, the core findings, including the target predictions from network pharmacology and the binding modes from molecular docking, are derived entirely from in silico simulations. These valuable hypotheses urgently require direct biochemical and pharmacological validation through subsequent in vitro and in vivo experiments. Secondly, molecular docking simulates a relatively static “lock-and-key” binding process. Although molecular dynamics simulations partially account for protein flexibility, the simulation time remains limited. The actual processes in vivo are highly dynamic, and complex factors such as protein conformational changes, post-translational modifications, and the formation of complexes with other biomacromolecules were not fully considered. In addition, while this study highlights the synergistic multi-target mechanism of curcumin, the current computational approach could not definitively identify a single most promising therapeutic target from the proposed core targets. The determination of a primary target responsible for the efficacy of curcumin requires further experimental validation. Furthermore, this study focused on the interaction between curcumin and its targets, without addressing its absorption, distribution, metabolism, and excretion properties in humans. The well-known challenges of curcumin’s low oral bioavailability and poor metabolic stability represent significant hurdles for its clinical translation, which this study did not assess. Finally, the pathogenesis of CSFP involves genetic, metabolic, inflammatory, and other multifaceted factors. The disease-target network constructed in this study may not fully encompass all pathogenesis-related genes, and its coverage of CSFP pathological pathways requires further refinement. Based on the findings of this study and the aforementioned limitations, future research efforts could focus on the following aspects. First, it is crucial to validate the direct effects of curcumin on core targets such as EGFR, PTGS2, and STAT3 through in vitro and in vivo experiments. Particularly, functional experiments (e.g., gene knockdown/overexpression, selective inhibition) should be designed to compare the contributions of different targets and to explore whether there exists a primary, most crucial target that dominates the therapeutic effect. Upon confirming its effects on individual targets, further experiments should be designed to explore its multi-target synergistic effects. To address the issue of low bioavailability, future studies could investigate the use of nanoparticle-based delivery systems (e.g., liposomes, polymer nanoparticles) or develop curcumin analogs/derivatives to enhance its water solubility, targeting capability, and metabolic stability, thereby improving its clinical efficacy. Finally, after obtaining sufficient preclinical evidence, consideration should be given to designing rigorous randomized controlled clinical trials specifically to evaluate the efficacy and safety of curcumin or its optimized formulations in CSFP patients, particularly regarding the frequency of angina attacks, coronary flow velocity, and quality of life. This would ultimately provide the high level of evidence-based medical support for promoting its clinical translation. Conclusions This study indicates that curcumin may exert therapeutic effects on CSFP through a “multi-target and multi-pathway” mechanism. It primarily acts on core targets such as EGFR, ICAM1, NFKB1, PTGS2, and STAT3 to modulate the HIF-1, TNF, and NF-κB signaling pathways. These findings provide a theoretical basis and mechanistic insights for the potential development of curcumin as a therapeutic candidate for CSFP. However, further validation through in vitro and in vivo experiments is required to confirm these computational predictions. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Coronary slow flow phenomenon Endothelial nitric oxide synthase False discovery rate Hypoxia-inducible factor-1 Online mendelian inheritance in man Protein data bank Protein-protein interaction Therapeutic target database Root-mean-square deviation Root-mean-square fluctuation Radius of gyration Molecular mechanics/generalized born surface area Author contributions The writing and content of this paper are the sole responsibility of Chentian Xue. The study design, data analysis, manuscript preparation, and revisions were significantly contributed to by Chentian Xue, Jian Kang, and Qing Zhu. Xiang Gao, Xize Wu, and Yue Yu were responsible for the study conceptualization and reviewed/edited the manuscript. Funding This research was supported by the Jiangsu Province Postgraduate Research and Practice Innovation Program (SJCX24_1035). Data availability The data analyzed during the current study are available from the following public databases: PubChem (https://pubchem.ncbi.nlm.nih.gov/), SwissTargetPrediction (http://www.swisstargetprediction.ch/), TargetNet (http://targetnet.scbdd.com/), Therapeutic Target Database (https://db.idrblab.net/ttd/), PharmMapper (https://lilab-ecust.cn/pharmmapper/), Similarity ensemble approach (https://sea.bkslab.org/), GeneCards (https://www.genecards.org/), Online Mendelian Inheritance in Man (https://omim.org/), Ensembl (https://www.ensembl.org/), DAVID (https://davidbioinformatics.nih.gov/), SRplot (http://www.bioinformatics.com.cn/srplot), GeneMANIA (http://genemania.org/), STRING (https://cn.string-db.org/), TRRUST (https://www.grnpedia.org/trrust/), TargetScan (http://www.targetscan.org/vert_72/), DIANA-microT (https://dianalab.e-ce.uth.gr/microt_webserver/#/), miRmap (https://mirmap.ezlab.org/), TarBase (https://dianalab.e-ce.uth.gr/tarbasev9), Protein Data Bank (https://www.rcsb.org/). In addition, the data related to this study have been included as supplementary material and are available as part of the manuscript submission. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Xiang Gao, Email: ntgx1964@163.com. Xize Wu, Email: 953935269@qq.com. Yue Yu, Email: 123178853@qq.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data analyzed during the current study are available from the following public databases: PubChem (https://pubchem.ncbi.nlm.nih.gov/), SwissTargetPrediction (http://www.swisstargetprediction.ch/), TargetNet (http://targetnet.scbdd.com/), Therapeutic Target Database (https://db.idrblab.net/ttd/), PharmMapper (https://lilab-ecust.cn/pharmmapper/), Similarity ensemble approach (https://sea.bkslab.org/), GeneCards (https://www.genecards.org/), Online Mendelian Inheritance in Man (https://omim.org/), Ensembl (https://www.ensembl.org/), DAVID (https://davidbioinformatics.nih.gov/), SRplot (http://www.bioinformatics.com.cn/srplot), GeneMANIA (http://genemania.org/), STRING (https://cn.string-db.org/), TRRUST (https://www.grnpedia.org/trrust/), TargetScan (http://www.targetscan.org/vert_72/), DIANA-microT (https://dianalab.e-ce.uth.gr/microt_webserver/#/), miRmap (https://mirmap.ezlab.org/), TarBase (https://dianalab.e-ce.uth.gr/tarbasev9), Protein Data Bank (https://www.rcsb.org/). In addition, the data related to this study have been included as supplementary material and are available as part of the manuscript submission.